公开(公告)号：EP1559446A1

公开(公告)日：2005-08-03

申请号：EP05001928.0

申请日：2005-01-31

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： Nishida, Akito Yamanouchi Pharmaceutical Co., Ltd. ,  Niwa, Akira Yamanouchi Pharmaceutical Co., Ltd. ,  Atsuta, Yutaka Yamanouchi Pharmaceutical Co., Ltd.

IPC分类号： A61P1/12 ,  A61K31/4184

CPC分类号： A61K31/4184

摘要： Use of ramosetron hydrochloride in a daily dose of 0.001 to 0.05 mg, or ramosetron or a pharmaceutically acceptable other salt thereof in an equimolar amount for the manufacture of a medicament for the treatment of diarrhea-predominant irritable bowel syndrome in male and female patients.

摘要翻译： 使用盐酸雷莫司琼以0.001至0.05mg的日剂量或雷莫司琼或其药学上可接受的其它盐以等摩尔量用于制造用于治疗男性和女性患者腹泻主要肠易激综合征的药物。

公开(公告)号：EP1541586A1

公开(公告)日：2005-06-15

申请号：EP03741500.7

申请日：2003-07-18

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD. ,  Harigai, Masayoshi

发明人： TAKEUCHI, Masahiro, c/o Yamanouchi Pharma. Co Ltd. ,  YAMAJI, Noboru, c/o Yamanouchi Pharma. Co. Ltd. ,  TAKASAKI, Jun, c/o Yamanouchi Pharma. Co., Ltd. ,  AKAMATSU, Masahiko, c/o Yamanouchi Pharma. Co Ltd. ,  TSUNOYAMA, Kazuhisa, c/o Yamanouchi Pharma. Co Ltd ,  HARIGAI, Masayoshi

IPC分类号： C07K14/47 ,  C12N15/12 ,  C12N5/10

CPC分类号： C07K14/4713 ,  C12Q1/6883 ,  C12Q2600/158

摘要： It is disclosed that novel polypeptides which has enhanced expression levels in the synovial tissues of human chronic rheumatoid arthritis (RA) patients compared with the synovial tissues of human osteoarthritis (OA) patients, polynucleotides encoding the polypeptides, vectors comprising the polynucleotides, transformant cells comprising the vectors and an antibody against the polypeptide. It is also disclosed that polynucleotides specifically hybridizing with the polynucleotides and having at least 15 nucleotides, a detection method which is useful for RA diagnosis, and a detection kit which is useful for RA diagnosis.

摘要翻译： 已经公开了与人类骨关节炎（OA）患者的滑膜组织相比，在人类慢性类风湿性关节炎（RA）患者的滑膜组织中具有增强的表达水平的新型多肽，编码多肽的多核苷酸，包含多核苷酸的载体，转化体细胞包含 载体和针对多肽的抗体。 还公开了与多核苷酸特异性杂交并具有至少15个核苷酸的多核苷酸，可用于RA诊断的检测方法以及可用于RA诊断的检测试剂盒。

公开(公告)号：EP1256576B1

公开(公告)日：2005-06-15

申请号：EP01904433.8

申请日：2001-02-14

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： MATSUHISA, Akira, c/o Yamanouchi Pharm. Co., Ltd. ,  KINOYAMA, Isao, c/o Yamanouchi Pharm. Co., Ltd. ,  TOYOSHIMA, Akira, c/o Yamanouchi Pharm. Co., Ltd. ,  NAKAHARA, Takahito c/o Yamanouchi Pharm. Co., Ltd. ,  TAKEUCHI, Masahiro, c/o Yamanouchi Pharm. Co., Ltd ,  OKADA, Minoru, c/o YAMANOUCHI PHARM. CO., Ltd.

IPC分类号： C07D235/02 ,  C07D401/06 ,  C07D403/06 ,  C07D401/14 ,  C07D401/12 ,  C07D417/06 ,  C07D413/06 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D487/04 ,  C07D491/048 ,  C07D213/38 ,  C07D333/68 ,  C07D235/14 ,  C07D307/52 ,  C07D209/14 ,  C07D333/40 ,  C07D211/58

CPC分类号： C07D213/64 ,  A61K31/36 ,  A61K31/416 ,  A61K31/4188 ,  A61K31/424 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/429 ,  A61K31/437 ,  A61K31/4453 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/551 ,  C07C233/41 ,  C07C235/14 ,  C07C237/04 ,  C07C255/24 ,  C07C255/25 ,  C07C255/58 ,  C07C259/06 ,  C07C271/28 ,  C07C311/37 ,  C07C317/28 ,  C07C323/25 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2602/10 ,  C07C2603/74 ,  C07D209/16 ,  C07D211/58 ,  C07D213/38 ,  C07D213/74 ,  C07D213/89 ,  C07D215/12 ,  C07D233/64 ,  C07D235/02 ,  C07D235/14 ,  C07D239/26 ,  C07D241/12 ,  C07D241/20 ,  C07D295/13 ,  C07D307/14 ,  C07D317/58 ,  C07D333/68 ,  C07D335/06 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/06 ,  C07D471/04 ,  C07D495/04

公开(公告)号：EP1518855A1

公开(公告)日：2005-03-30

申请号：EP03761820.4

申请日：2003-06-26

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： NAGASHIMA, S., c/o Yamanouchi Pharm. Co., Ltd. ,  NAGATA, H., c/o Yamanouchi Pharm. Co., Ltd. ,  IWATA, M., c/o Yamanouchi Pharm. Co., Ltd. ,  YOKOTA, M., c/o Yamanouchi Pharm. Co., Ltd. ,  MORITOMO, H., c/o Yamanouchi Pharm. Co., Ltd. ,  NAKAI, E., c/o Yamanouchi Pharm. Co., Ltd. ,  KUROMITSU, S.,c/o Yamanouchi Pharm. Co., Ltd. ,  OHGA, K., c/o Yamanouchi Pharm. Co., Ltd. ,  TAKEUCHI, M., c/o Yamanouchi Pharm. Co., Ltd.

IPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61P11/00 ,  A61P11/06 ,  A61P43/00 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  A61K31/55 ,  C07D405/14

CPC分类号： C07D403/12 ,  C07D239/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D451/04 ,  C07D453/02 ,  C07D471/10 ,  C07D487/08

摘要： A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided.
A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

摘要翻译： 提供可用于预防或治疗其中涉及STAT6的呼吸系统疾病的化合物，特别是哮喘，慢性阻塞性肺疾病等。 嘧啶衍生物或其盐在2位具有可被特定取代基取代的芳氨基或芳基乙氨基，在4位具有被苄基等取代的氨基，以及氨基甲酰基， 可以在5位被取代。

公开(公告)号：EP1481683A1

公开(公告)日：2004-12-01

申请号：EP03012123.0

申请日：2003-05-30

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： Appeldoorn, Chantal Catharina Maria C/o LACDR ,  Biessen, Erik Anna Leonardus C/o LACDR ,  Van Berkel, Theodorus Josephus Cornelis C/o LACDR

IPC分类号： A61K38/00

CPC分类号： A61K38/08

摘要： P-selectin targeting ligand molecules are provided as well as compositions, including kits, which comprise such P-selectin targeting ligand molecules, such composition being useful for use as pharmaceutical formulations which can be administered safely and effectively and as diagnostic formulations.

摘要翻译： 提供了P-选择素靶向配体分子以及包含这种P-选择素靶向配体分子的组合物的组合物，所述组合物可用作可安全且有效地施用的药物制剂以及作为诊断制剂。

公开(公告)号：EP1475095A1

公开(公告)日：2004-11-10

申请号：EP03705125.7

申请日：2003-02-13

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD. ,  Kyukyu Pharmaceutical Co., Ltd.

发明人： TSUJI, Yasuhiro c/o KYUKYU PHARMACEUT. CO., LTD. ,  TAMURA, Kei c/o KYUKYU PHARMACEUT. CO., LTD. ,  YAMAZAKI, Yuuhiro c/o KYUKYU PHARMACEUT.CO., LTD. ,  SAWAI, Yoshihiro c/o KYUKYU PHARMACEUT.CO., LTD.

IPC分类号： A61K31/663 ,  A61K9/06 ,  A61K9/08 ,  A61K9/10 ,  A61K9/70 ,  A61K47/04 ,  A61K47/22 ,  A61P3/14 ,  A61P19/08 ,  A61P19/10 ,  A61P43/00

CPC分类号： A61K9/7053 ,  A61K9/0014 ,  A61K9/7076 ,  A61K31/663 ,  A61K47/06 ,  A61K47/22 ,  A61K47/26

摘要： A bisphosphonic acid derivative-containing percutaneous preparation of an excellent percutaneous permeability, comprising a bisphosphonic acid derivative such as incadronic acid, minodronic acid, etc., or pharmaceutically acceptable salts thereof, a solubilizing agent for the derivative or pharmaceutically acceptable salts thereof, and an amphiphilic solubilizing auxiliary agent, which may optionally contain a suspension-type base such as a polyvalent alcohol, a higher fatty acid ester, a liquid hydrocarbon or a vegetable oil, etc. This preparation has an excellent percutaneous permeability, reduces burdens on the patient, does not deteriorate the patient's compliance even in the administration over a prolonged period of time and can achieve the therapeutic effects in a short period of time.

摘要翻译： 含有二膦酸衍生物如米多昔康酸等的双膦酸衍生物或其药学上可接受的盐，其衍生物或其药学上可接受的盐的增溶剂，和 两性增溶助剂，其可任选地含有悬浮型碱，如多元醇，高级脂肪酸酯，液体烃或植物油等。该制剂具有优异的经皮通透性，减轻患者的负担， 即使在长时间的施用中也不会降低患者的依从性，并且可以在短时间内达到治疗效果。

公开(公告)号：EP1445253A1

公开(公告)日：2004-08-11

申请号：EP02781759.2

申请日：2002-11-13

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： KOSHIO, H., c/o Yamanouchi Pharmaceutical Co., Ltd ,  TSUKAMOTO, I., c/o Yamanouchi Pharm. Co., Ltd. ,  KURAMOCHI, T., c/o Yamanouchi Pharm. Co., Ltd. ,  AKAMATSU, S., c/o Yamanouchi Pharm. Co., Ltd. ,  SAITOH, C., c/o Yamanouchi Pharmaceutical Co. Ltd.

IPC分类号： C07D223/16 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D409/14 ,  C07D417/14 ,  C07D401/06 ,  C07D403/06 ,  C07D405/14 ,  A61K31/55 ,  A61P7/12 ,  A61P13/00 ,  A61P43/00

CPC分类号： C07D223/16 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

摘要： 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin V 2 activity and are useful for a drug for the treatment of central diabetes insipidus and/or nocturia.

摘要翻译： 4,4-二氟-1,2,3,4-四氢-5H-1-苯并氮杂衍生物，其具有优异的精氨酸加压素V2活性，并且可用于治疗中枢性尿崩症和/或夜尿症的药物。

公开(公告)号：EP1443901A2

公开(公告)日：2004-08-11

申请号：EP02782303.8

申请日：2002-11-12

申请人： Yamanouchi Pharma Technologies, Inc. ,  YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： ROGERS, Victoria ,  DOR, Philippe, J., M. ,  FIX, Joseph, A. ,  KOJIMA, Hiroyuki ,  SAKO, Kazuhiro

IPC分类号： A61K9/00 ,  A61K9/127 ,  A61K9/52 ,  A61K9/22 ,  A61K9/14 ,  A61K31/78

CPC分类号： A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054

摘要： This invention relates to novel oral sustained-release formulations for delivery of an active agent (e.g., a drug), especially a highly water soluble drug. More particularly, this invention relates to novel formulations comprising a micelle-forming drug having a charge and at least one polymer having an opposite charge. Methods of using the novel formulations are also provided.

公开(公告)号：EP1413578A1

公开(公告)日：2004-04-28

申请号：EP02751685.5

申请日：2002-07-25

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： KATO, Yoshinori ,  HARADA, Hironori ,  KUROTANI, Masahiro ,  TODA, Haruhiko ,  SAKAMOTO, Kenichirou

IPC分类号： C07D239/52 ,  A61K31/505 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00

CPC分类号： C07D239/52

摘要： Novel crystals of a potassium salt of ( E )-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethenesulfonamide, a preparation process thereof, and novel solvates of ( E )-N-[6-methoxy-5-(2-ethoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethenesulfonamide.

摘要翻译： 结晶的（E）-N - [（6-甲氧基-5-（2-甲氧基苯氧基）-2-嘧啶-2-基）嘧啶-4-基] -2-苯基乙烯基磺酰胺（I）的钾盐是新的。 结晶的（E）-N - [（6-甲氧基-5-（2-甲氧基苯氧基）-2-嘧啶-2-基）嘧啶-4-基]式（I）的钾盐-2-苯基乙烯基磺酰胺是新的。 被包括为（Ⅰ），用乙酸乙酯和乙醇溶剂化物[图像]的独立claimsoft。 活动：心血管基因。 低血压。 作用机理：内皮素激动剂-A; 内皮素拮抗剂-A。

公开(公告)号：EP1374858A2

公开(公告)日：2004-01-02

申请号：EP03076769.3

申请日：2002-05-08

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： Takaishi, Yuuki, c/o Yamanouchi Pharma. Co., Ltd ,  Mizumoto, Takao, c/o Yamanouchi Pharma. Co., Ltd ,  Masuda, Yoshinori, c/o Yamanouchi Pharma. Co., Ltd

IPC分类号： A61K9/20

CPC分类号： A61K9/0056 ,  A61K9/2018

摘要： The present invention relates to a quick-disintegrating tablet in the buccal cavity comprising a drug, a diluent, and a saccharide with a relatively lower melting point than the drug and the diluent, which is obtained by uniformly mixing the saccharide with a low melting point in the tablet so that a bridge will be formed between said drug and/or said diluent particles by the product of melting and then solidification of this saccharide with a low melting point. Moreover, the present invention relates to a method of manufacturing a quick-disintegrating tablet in the buccal cavity comprising a drug, a diluent and a saccharide with a relatively lower melting point than the drug and the diluent, which comprises (a) the process whereby tablet starting materials including a drug, a diluent, and a saccharide with a relatively lower melting point than the drug and the diluent are molded under the low pressure necessary for retaining the shape of a tablet, (b) the process whereby the molded product obtained in process (a) is heated to at least the temperature at which this saccharide with a low melting point will melt, and (c) the process whereby the molded product obtained in process (b) is cooled to at least the temperature at which the molten saccharide with a low melting point solidifies.
The present invention presents a quick-disintegrating tablet in the buccal cavity that can be used for practical purposes in that it has almost the same properties as conventional oral pharmaceutical tablets, that is, it has sufficient tablet strength that it can be used with automatic unit dosing machines, and it is produced by conventional tableting machines, and a manufacturing method thereof. Moreover, the present invention presents a quick-disintegrating tablet in the buccal cavity which, in comparison to conventional quick-disintegrating tablets in the buccal cavity, has increased tablet strength and an improved friability without prolonging the disintegration time in the buccal cavity, and a manufacturing method thereof.

摘要翻译： 本发明涉及颊腔中的快速崩解片剂，其包含药物，稀释剂和具有比药物和稀释剂相对较低的熔点的糖，其通过将糖均匀混合到低熔点 在片剂中使得在所述药物和/或所述稀释剂颗粒之间将由低熔点的这种糖的熔化然后凝固的产物形成桥。 此外，本发明涉及在口腔中制造快速崩解片剂的方法，其包括药物，稀释剂和具有比药物和稀释剂更低的熔点的糖类，其包括（a） 包含药物，稀释剂和具有比药物和稀释剂相对较低熔点的糖类的片剂起始材料在保持片状形状所需的低压下成型，（b）所得成型品 在加工过程（a）中被加热到至少具有低熔点的糖的熔融温度，和（c）将方法（b）中得到的模塑产物冷却至至少在 具有低熔点的熔融糖固化。 本发明提供了一种颊腔中的快速崩解片，其可用于实际目的，因为其具有与常规口服药物片剂几乎相同的性质，即其具有足够的片剂强度，其可以是 与自动单位计量机一起使用，并且由常规压片机生产，及其制造方法。 此外，本发明在口腔中提供了快速崩解片剂，其与口腔中的常规快速崩解片剂相比具有增加的片剂强度和改善的脆性，而不延长颊腔内的崩解时间，并且 其制造方法。